A Novel Panel of Cerebrospinal Fluid Biomarkers for the Differential Diagnosis of Alzheimer’s Disease versus Normal Aging and Frontotemporal Dementia

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Dementia and Geriatric Cognitive Disorders

• Publication date

  2007-10-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000110576PMID 17971664
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease.

  2008cited by this paper
• Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline

  2007cited by this paper
• Cystatin C reduces the in vitro formation of soluble Aβ1‐42 oligomers and protofibrils

  2007cited by this paper
• Cystatin C in cerebrospinal fluid and multiple sclerosis

  2007cited by this paper
• Alzheimer's disease

  2006cited by this paper
• Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease

  2005cited by this paper
• Chromogranin peptides in Alzheimer's disease.

  2004cited by this paper
• CSF markers for incipient Alzheimer's disease.

  2003cited by this paper
• A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease

  2003cited by this paper
• The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification.

  2002cited by this paper
• Tau and A&bgr;42 protein in CSF of patients with frontotemporal degeneration

  2002cited by this paper
• Synaptic proteins in Alzheimer’s disease

  2002cited by this paper
• Frontotemporal Dementia and Alzheimer’s Disease:Differential Diagnosis

  1999cited by this paper
• Neuropathology of Alzheimer's disease: a critical update.

  1998cited by this paper
• Molecular basis for amyloidosis related to hereditary brain hemorrhage.

  1996cited by this paper
• Cathepsin G: localization in human cerebral cortex and generation of amyloidogenic fragments from the beta-amyloid precursor protein.

  1994cited by this paper
• Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups.

  1994cited by this paper
• Vascular dementia

  1993cited by this paper
• Alzheimer's disease : clinical features and differential diagnosis

  1993cited by this paper
• Diagnostic value of analysis of cystatin C and protein HC in biological fluids.

  1992cited by this paper
• Synaptic pathology in Alzheimer's disease: immunological data for markers of synaptic and large dense-core vesicles.

  1992cited by this paper
• Different forms of human cystatin C.

  1990cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper
• Cathepsin A in human brain and spleen.

  1973cited by this paper
• Cathepsin A in human brain and spleen (Short Communication)

  1973cited by this paper

• Asparagine endopeptidase (AEP) inhibitor formulation via zein-based nanoparticle improves the therapeutic efficacy toward Alzheimer's disease

  2025cites this paper
• Small peptide CSF fingerprint of amyotrophic lateral sclerosis.

  2024cites this paper
• Association Between the Gut Microbiota and Alzheimer’s Disease: An Update on Signaling Pathways and Translational Therapeutics

  2024cites this paper
• Small peptide fingerprint (peptidomics) of Amyotrophic Lateral Sclerosis in CSF

  2023cites this paper
• Longitudinal Spatial Relationships Between Atrophy and Hypometabolism Across the Alzheimer’s Disease Continuum

  2023cites this paper
• C/EBPβ/AEP Signaling Drives Alzheimer’s Disease Pathogenesis

  2023cites this paper
• Inhibition of asparagine endopeptidase (AEP) effectively treats sporadic Alzheimer’s disease in mice

  2023cites this paper
• Changes in Serum Cystatin C Levels and the Associations With Cognitive Function in Alzheimer's Disease Patients

  2022cites this paper
• Endosomal-Lysosomal and Autophagy Pathway in Alzheimer’s Disease: A Systematic Review and Meta-Analysis

  2022cites this paper
• Extracellular protein components of amyloid plaques and their roles in Alzheimer’s disease pathology

  2021cites this paper
• Proteomic Analysis of Hydromethylthionine in the Line 66 Model of Frontotemporal Dementia Demonstrates Actions on Tau-Dependent and Tau-Independent Networks

  2021cites this paper
• Fluid Biomarkers of Frontotemporal Lobar Degeneration.

  2021cites this paper
• The serum level of cystatin C does not predict dopaminergic cell death in substantia nigra, evidence from 6-hydroxydopamine-induced animal model of Parkinson's disease

  2020cites this paper
• Chromogranin A Analysis in the Differential Diagnosis Across Lewy Body Disorders

  2020cites this paper
• VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies

  2019cites this paper
• Hyphenated Mass Spectrometry Techniques in the Diagnosis of Amyloidosis.

  2019cites this paper
• Aberrant Levels of Cystatin C in Amyotrophic Lateral Sclerosis: a Systematic Review and Meta Analysis

  2018cites this paper
• A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer's Disease

  2018cites this paper
• Characteristics of C‐terminal, β‐amyloid peptide binding fragment of neuroprotective protease inhibitor, cystatin C

  2017cites this paper
• Evolving Relevance of Neuroproteomics in Alzheimer's Disease.

  2017cites this paper
• Evaluation of Different Factors Leading to the Genesis of Alzheimer’s Disease: Research Proposal on Dementia

  2017cites this paper
• Neuroproteomics

  2017cites this paper
• Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics

  2016cites this paper
• Proteomics and Human Diseases

  2016cites this paper
• Molecular Biomarkers for Diagnosis & Therapies of Alzheimer’s Disease

  2016cites this paper
• Blood-based biomarkers of Alzheimer's disease: diagnostic algorithms and new technologies.

  2016cites this paper
• Application of Systems Theory in Longitudinal Studies on the Origin and Progression of Alzheimer's Disease.

  2016cites this paper
• Cystatin C in aging and in Alzheimer's disease.

  2016cites this paper
• Asparagine endopeptidase is an innovative therapeutic target for neurodegenerative diseases

  2016cites this paper
• Cerebrospinal Fluid Biomarkers in Familial Forms of Alzheimer's Disease and Frontotemporal Dementia

  2015cites this paper
• Cerebrospinal fluid proteomics and protein biomarkers in frontotemporal lobar degeneration: Current status and future perspectives.

  2015cites this paper
• Visualization of different characteristics of cerebrospinal fluid with acute encephalopathy and febrile seizures using pattern recognition analysis of 1H NMR

  2015cites this paper
• Direct analytical sample quality assessment for biomarker investigation: Qualifying cerebrospinal fluid samples

  2014cites this paper
• Biological function and clinical relevance of chromogranin A and derived peptides

  2014cites this paper
• Cerebrospinal fluid analysis in Alzheimer’s disease: technical issues and future developments

  2014cites this paper
• Analysis of global protein profile of heart from cloned piglets

  2013cites this paper
• Quantitative Label-Free Proteomics for Discovery of Biomarkers in Cerebrospinal Fluid: Assessment of Technical and Inter-Individual Variation

  2013cites this paper
• Alterations of CSF Cystatin C Levels and Their Correlations with CSF Αβ40 and Αβ42 Levels in Patients with Alzheimer's Disease, Dementia with Lewy Bodies and the Atrophic Form of General Paresis

  2013influential citation
• Translational proteomics in Alzheimer's disease and related disorders.

  2013cites this paper
• Can proteomics yield insight into aging aorta?

  2013cites this paper
• ANALYSIS OF GLOBAL PROTEIN PROFILE OF HEART FROM CLONED PIGLETS Thesis submitted in partial fulfillment of the requirements for the degree of Masters in Technology in BIOTECHNOLOGY

  2013cites this paper
• Alzheimer's disease biomarkers: correspondence between human studies and animal models.

  2013cites this paper
• Alzheimer's disease biomarkers in animal models: closing the translational gap.

  2013cites this paper
• Protein profiling of cerebrospinal fluid.

  2012cites this paper
• Protein Clearance Mechanisms of Alpha-Synuclein and Amyloid-Beta in Lewy Body Disorders

  2012cites this paper
• Cystatin C in Alzheimer's disease

  2012cites this paper
• Monitoring CSF Proteome Alterations in Amyotrophic Lateral Sclerosis: Obstacles and Perspectives in Translating a Novel Marker Panel to the Clinic

  2012cites this paper
• Biomarkers for Alzheimer Disease in Cerebrospinal Fluid, Urine, and Blood

  2012cites this paper
• Protein Markers for the Differential Diagnosis of Vascular Dementia and Alzheimer's Disease

  2012cites this paper
• Peptidome Analysis of Cerebrospinal Fluid by LC-MALDI MS

  2012cites this paper
• A novel peptidomics approach to detect markers of Alzheimer's disease in cerebrospinal fluid.

  2012cites this paper
• Use of proteomic methods in the analysis of human body fluids in Alzheimer research

  2012cites this paper
• Label-free quantitative LC-MS proteomics of Alzheimer's disease and normally aged human brains.

  2012cites this paper
• Biomarkers of Basic Activities of Daily Living in Alzheimer's Disease

  2012cites this paper
• Recent biomarker approaches in the diagnosis of frontotemporal lobar degeneration/Neurochemische Ansätze in der Diagnose der Frontotemporalen Lobärdegeneration

  2012cites this paper
• Identification of Novel Fluid Biomarkers for Alzheimer's Disease

  2012cites this paper
• Identification of a novel biomarker candidate, a 4.8-kDa peptide fragment from a neurosecretory protein VGF precursor, by proteomic analysis of cerebrospinal fluid from children with acute encephalopathy using SELDI-TOF-MS

  2011cites this paper
• Proteomic research in psychiatry

  2011cites this paper
• Biomarkers in Alzheimer's disease drug development

  2011cites this paper
• The extended granin family: structure, function, and biomedical implications.

  2011cites this paper
• Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: The Present and the Future

  2011cites this paper
• Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease

  2011cites this paper
• Multiplexed Immunoassay Panel Identifies Novel CSF Biomarkers for Alzheimer's Disease Diagnosis and Prognosis

  2011cites this paper
• New insights into biological markers of frontotemporal lobar degeneration spectrum.

  2010cites this paper
• Adult Neurogenesis: A Potential Tool for Early Diagnosis in Alzheimer's Disease?

  2010cites this paper
• The CST3 BB Genotype and Low Cystatin C Cerebrospinal Fluid Levels are Associated with Dementia in Lewy Body Disease

  2010cites this paper
• CSF Biomarkers

  2010cites this paper
• Glycoproteomics in neurodegenerative diseases.

  2010cites this paper
• An update on clinical proteomics in Alzheimer’s research

  2010cites this paper
• Proteomic analysis of endoscopically (endoscopic pancreatic function test) collected gastroduodenal fluid using in‐gel tryptic digestion followed by LC‐MS/MS

  2010cites this paper
• Granins as disease-biomarkers: translational potential for psychiatric and neurological disorders.

  2010cites this paper
• Biomarkers in Clinical Drug Development: Parallel Analysis of Alzheimer Disease and Multiple Sclerosis

  2010cites this paper
• Proteomic investigations of the ventriculo-lumbar gradient in human CSF.

  2010cites this paper
• Recent cerebrospinal fluid biomarker studies of Alzheimer’s disease

  2010cites this paper
• Primary progressive aphasia: clinicopathological correlations

  2010cites this paper
• Regulation of gene expression by non-protein-coding RNAs

  2009cites this paper
• Reduced Levels of Amyloid-β-Binding Proteins in Cerebrospinal Fluid from Alzheimer's Disease Patients

  2009cites this paper
• Proteomics as a New Tool for Biomarker-Discovery in Neuropsychiatric Disorders

  2009cites this paper
• Milk Fat Globule Protein Epidermal Growth Factor-8: A Pivotal Relay Element Within the Angiotensin II and Monocyte Chemoattractant Protein-1 Signaling Cascade Mediating Vascular Smooth Muscle Cells Invasion

  2009cites this paper
• Novel cerebrospinal fluid biomarkers of axonal degeneration in frontotemporal dementia.

  2008cites this paper
• Proteomics of Human Neurodegenerative Diseases

  2008cites this paper
• Why Do So Many Drugs for Alzheimer's Disease Fail in Development? Time for New Methods and New Practices?

  2008cites this paper
• Biomarkers for cognitive impairment and dementia in elderly people.

  2008cites this paper
• Becker Digital Commons

  year unknowncites this paper